Journal of Veterinary Pharmacology and Therapeutics · 2000 · 61 citations · 37 references
MedicinePharmacokineticsPharmacologyBioavailabilityChemotherapyClinical PharmacologyDrug DispositionPharmacokinetics Of AntimicrobialsVeterinary Antimicrobial TherapyVeterinary ChemotherapyActive Metabolite KineticsFluoroquinolone AntibioticsMaximum Observed ConcentrationPharmacokinetic ParametersPharmacokinetics Of Veterinary AntimicrobialsTime To Maximum Concentration ComparisonVeterinary PharmacokineticsWashout Periods
Plasma, urine, and skin drug concentrations were determined for dogs (n=12) given five daily oral doses of marbofloxacin (MAR) (2.75 mg/kg), enrofloxacin (ENR) (5.0 mg/kg) or difloxacin (DIF) (5.0 mg/kg). Concentrations of the active metabolite of ENR, ciprofloxacin (CIP), were also determined. The three-period, three-treatment crossover experimental design included a 21-day washout period between treatments. Area under the plasma drug concentration vs. time curve (AUC0-last, microg/mLxh of MAR was greater than for ENR, CIP, ENR/CIP combined, and DIF. Maximum concentration (Cmax) of MAR was greater than ENR, CIP, and DIF. Time of maximum plasma concentration (Tmax) was similar for MAR and DIF; Tmax occurred earlier for ENR and later for CIP. Plasma half-life (t1/2) of MAR was longer than for ENR, CIP, and DIF. Urine concentrations of DIF were less than MAR or ENR/CIP combined, but urine concentrations of MAR and ENR/CIP combined did not differ. DIF skin concentrations were less than the concentrations of MAR or ENR/CIP combined 2 h after dosing, but skin concentrations of MAR and ENR/CIP combined did not differ.
37
American Journal of Veterinary Research.
PubMed · 1940 · 5.4K citations · Full text
Agriculture, Animal Sciences, Veterinary Clinical Sciences +2
ORAL CIPROFLOXACIN THERAPY OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA
BrianE. Scully, MichaelF. Parry, HaroldC. Neu et al. · The Lancet · 1986 · 156 citations
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +14